{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:03:02Z","timestamp":1761487382217},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1995,3,1]],"date-time":"1995-03-01T00:00:00Z","timestamp":794016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[1995,3]]},"DOI":"10.1007\/bf01571406","type":"journal-article","created":{"date-parts":[[2005,4,27]],"date-time":"2005-04-27T16:20:35Z","timestamp":1114618835000},"page":"35-40","source":"Crossref","is-referenced-by-count":19,"title":["Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Carla I.","family":"Falkson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01571406_CR1","first-page":"399","volume":"17","author":"A.M. Merwe van der","year":"1971","unstructured":"van der Merwe, A.M., Falkson, G., van Eden, E.B.et al. (1971) Metastatic malignant melanoma.Med Proc 17, 399\u2013405.","journal-title":"Med Proc"},{"key":"BF01571406_CR2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000224680","volume":"26","author":"D.E. Wagner","year":"1972","unstructured":"Wagner, D.E., Ramirez, G., Weiss, A.J.et al. (1972) Combination phase I\u2013II study of imidazole-carboxamide (NSC 45388).Oncology 26, 310\u20136.","journal-title":"Oncology"},{"key":"BF01571406_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2964(72)90087-4","volume":"8","author":"S.K. Carter","year":"1972","unstructured":"Carter, S.K. and Friedman, M.A. (1972) 5-(3,3-dimethyl-1-triazenoz)-imidazole-4-carboxamide (DTIC,DIC,NSC 43588). A new antitumor agent against malignant melanoma.Eur. J. Cancer,8, 85\u201392.","journal-title":"Eur. J. Cancer"},{"key":"BF01571406_CR4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/1097-0142(197502)35:2<368::AID-CNCR2820350211>3.0.CO;2-C","volume":"35","author":"J.H. Moon","year":"1975","unstructured":"Moon, J.H., Gailani, S., Cooper, M.R.et al. (1975) Comparison of the combination of 1,3-bis-(2-chloroethyl)-1-nitrosourea(BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazeno)imidazole 4-carboxamide (DTIC) in the treatment of malignant melanoma.Cancer 35, 368\u201371.","journal-title":"Cancer"},{"key":"BF01571406_CR5","first-page":"183","volume":"60","author":"R.D. Johnson","year":"1976","unstructured":"Johnson, R.D., Metter, G., Wilson, W.et al. (1976) Phase I evaluation of DTIC (NSC 43588) and other studies in malignant melanoma in the Central Oncology Group.Cancer Treat. Rep. 60, 183\u20137.","journal-title":"Cancer Treat. Rep."},{"key":"BF01571406_CR6","first-page":"189","volume":"60","author":"J.J. Constanzi","year":"1976","unstructured":"Constanzi, J.J. (1976) DTIC (NSC 43588) studies in the South-West Oncology Group.Cancer Treat. Rep. 60, 189\u201392.","journal-title":"Cancer Treat. Rep."},{"key":"BF01571406_CR7","first-page":"193","volume":"60","author":"P.P. Carbone","year":"1976","unstructured":"Carbone, P.P. and Costello, W. (1976) Eastern Cooperative Group studies with DTIC (NSC 43588).Cancer Treat. Rep. 60, 193\u20138.","journal-title":"Cancer Treat. Rep."},{"key":"BF01571406_CR8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cpt1971126955","volume":"12","author":"L. Nathanson","year":"1971","unstructured":"Nathanson, L., Wolter, J., Horton, J.et al. (1971) Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.Clin. Pharmacol. Ther. 12, 955\u201362.","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01571406_CR9","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1097-0142(197709)40:3<1010::AID-CNCR2820400308>3.0.CO;2-C","volume":"47","author":"M.E. Costanza","year":"1977","unstructured":"Costanza, M.E., Nathanson, L., Schoenfeld, D.et al. (1977) Results with Methyl-CCNU and DTIC in Metastatic Melanoma.Cancer 47, 1010\u201315.","journal-title":"Cancer"},{"key":"BF01571406_CR10","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J","volume":"47","author":"G.J.II Hill","year":"1981","unstructured":"Hill, G.J.II, Moss, S.E., Golomb, F.M.et al. (1981) DTIC and combination therapy for melanoma.Cancer 47, 2556\u201362.","journal-title":"Cancer"},{"key":"BF01571406_CR11","first-page":"1989","volume":"63","author":"G.J.II Hill","year":"1979","unstructured":"Hill, G.J.II, Metter, G.E., Krementz, E.T.et al. (1979) DTIC and combination therapy for melanoma.Cancer Treat. Rep. 63, 1989\u201392.","journal-title":"Cancer Treat. Rep."},{"key":"BF01571406_CR12","first-page":"176","volume":"1","author":"S.D. Luikart","year":"1982","unstructured":"Luikart, S.D. and Kirkwood, J.M. (1982) A comparison of vinblastine, bleomycin and cisplatin (VBD) with dacarbazine (DTIC) in metastatic melanoma. (Abstr)Proc. Am. Soc. Clin. Oncol. 1, 176.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR13","first-page":"671","volume":"56","author":"G. Falkson","year":"1972","unstructured":"Falkson, G., van der Merwe, A.M. and Falkson, H.C. (1972) Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC 82196) in the treatment of metastatic malignant melanoma.Cancer Chemother. Rep. 56, 671\u201377.","journal-title":"Cancer Chemother. Rep."},{"key":"BF01571406_CR14","first-page":"1499","volume-title":"Cancer: Principles and Practices of Oncology","author":"C.M. Balch","year":"1989","unstructured":"Balch, C.M., Houghton, A. and Peters, L. (1989) Cutaneous melanoma. In De Vita, Jr, S. Hellman and S.A. Rosenberg (eds),Cancer: Principles and Practices of Oncology, 3rd edn, pp. 1499\u2013542, Philadelphia PA: Lippincot.","edition":"3rd edn"},{"key":"BF01571406_CR15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.1984.2.9.1002","volume":"2","author":"E.T. Creagan","year":"1984","unstructured":"Creagan, E.T., Ahmann, D.L., Green, S.J.et al. (1984) Phase II study of low-dose recombinant leukocyte A in disseminated malignant melanoma.J. Clin. Oncol. 2, 1002\u20135.","journal-title":"J. Clin. Oncol."},{"key":"BF01571406_CR16","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/1097-0142(19841215)54:12<2844::AID-CNCR2820541205>3.0.CO;2-Q","volume":"54","author":"E.T. Creagan","year":"1984","unstructured":"Creagan, E.T., Ahmann, D.L. and Green, S.J. (1984) Phase II study of recombinant leukocyte A (r-IFN\u03b1A) in disseminated malignant melanoma.Cancer 54, 2844\u20139.","journal-title":"Cancer"},{"key":"BF01571406_CR17","first-page":"126","volume":"4","author":"E.T. Creagan","year":"1985","unstructured":"Creagan, E.T., Ahmann, D.L., Green, S.J.et al. (1985) Recombinant leukocyte interferon (IFN-\u03b1A) plus cimetidine in disseminated malignant melanoma (DMM). (Abstr C-491).Proc. Am. Soc. Clin. Oncol. 4, 126.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR18","first-page":"54","volume":"3","author":"D.E. Slater","year":"1984","unstructured":"Slater, D.E., Krown, S.E., Pinsky, C.M.et al. (1984) Human leukocyte (alpha) interferon (HuIFN-alfa(Le)) and cimetidine in malignant melanoma (Abstr C-210)Proc. Am. Soc. Clin. Oncol. 3, 54.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR19","first-page":"57","volume":"2","author":"M.S. Ernstoff","year":"1983","unstructured":"Ernstoff, M.S., Reiss, M., Davis, C.A.et al. (1983) Intravenous (IV) recombinant alpha-2 interferon (IFN-\u03b1-2) in metastatic melanoma. (Abstr C-222)Proc. Am. Soc. Clin. Oncol. 2, 57.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR20","first-page":"51","volume":"3","author":"M.J. Hawkins","year":"1984","unstructured":"Hawkins, M.J., McCune, C.S., Speyer, J.L.et al. (1984) Recombinant alpha 2 interferon (IFN\u03b1-2) (SCH 30500) in patients with metastatic malignant melanoma (MMM). An ECOG pilot study (Abstr C-195)Proc. Am. Soc. Clin. Oncol. 3, 51.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR21","first-page":"60","volume":"3","author":"W.A. Robinson","year":"1984","unstructured":"Robinson, W.A., Kirkwood, J., Harvey, H.et al. (1984) Effective use of recombinant human \u03b1-2 interferon (IFN\u03b12) \u03b12) in metastatic malignant melanoma (MMM): A comparison of two regimens (Abstr C-234)Proc. Am. Soc. Clin. Oncol. 3, 60.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","volume":"2","author":"J.M. Kirkwood","year":"1984","unstructured":"Kirkwood, J.M. and Ernstoff, M.S. (1984) Interferons in the treatment of human cancer.J. Clin. Oncol. 2, 336\u201352.","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"BF01571406_CR23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000421-199012000-00004","volume":"13","author":"J.R. Neefe","year":"1990","unstructured":"Neefe, J.R., Legha, S.S., Markowitz, A.et al. (1990) Phase II study of recombinant interferon in malignant melanoma.Am. J. Clin. Oncol. (CCT) 13 (6), 472\u20136.","journal-title":"Am. J. Clin. Oncol. (CCT)"},{"key":"BF01571406_CR24","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1111\/1523-1747.ep12875512","volume":"95","author":"E.T. Creagan","year":"1990","unstructured":"Creagan, E.T., Schaid, D.J., Ahmann, D.L.et al. (1990) Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.J. Invest. Dermatol. 95, 188S-192S.","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"BF01571406_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/jnci\/82.12.1062","volume":"82","author":"J.M. Kirkwood","year":"1990","unstructured":"Kirkwood, J.M., Ernstoff, M.S., Giuliano, A.et al. (1990) Interferon \u03b1-2a and Dacarbazine in melanoma.J. Nat. Can. Inst. 82 (12), 62.","journal-title":"J. Nat. Can. Inst."},{"key":"BF01571406_CR26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.1991.9.8.1403","volume":"9","author":"C.I. Falkson","year":"1991","unstructured":"Falkson, C.I., Falkson, G. and Falkson, H.C. (1991) Improved Results With the Addition of Interferon alfa-2b to Dacarbazine in the Treatment of Patients With Metastatic Malignant Melanoma.J. Clin. Oncol. 9, 1403\u20138.","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"BF01571406_CR27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00390495","volume":"114","author":"T.I. Mughal","year":"1988","unstructured":"Mughal, T.I., Robinson, W.A., Thomas, M.R.et al. (1988) Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.J. Cancer Res. Clin. Oncol. 114 (1), 108\u20139.","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BF01571406_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-103-1-32","volume":"103","author":"J.M. Kirkwood","year":"1985","unstructured":"Kirkwood, J.M., Ernstoff, M.S., Davis, C.A.et al. (1985) Comparison of intramuscular and intravenous recombinant alpha 2-Inteferon in melanoma and other cancers.Ann. Int. Med. 103, 32\u20136.","journal-title":"Ann. Int. Med."},{"issue":"Suppl","key":"BF01571406_CR29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00207264","volume":"5","author":"T. Dorval","year":"1987","unstructured":"Dorval, T., Palangie, T., Jouve, M., Giralt, E., Falcoff, E. and Schwab, D. (1987) Treatment of metastatic malignant melanoma with recombinant interferon alfa 2b.Invest. New Drugs 5 (Suppl), 61\u20134.","journal-title":"Invest. New Drugs"},{"key":"BF01571406_CR30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/1097-0142(19860715)58:2<215::AID-CNCR2820580202>3.0.CO;2-P","volume":"58","author":"T. Dorval","year":"1986","unstructured":"Dorval, T., Palangie, T., Jouve, M.et al. (1986) Clinical Phase II Trial of recombinant DNA interferon (Interferon alfa 2b) in patients with metastatic malignant melanoma.Cancer 58, 215\u20138.","journal-title":"Cancer"},{"key":"BF01571406_CR31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000226960","volume":"48","author":"T.I. Mughal","year":"1991","unstructured":"Mughal, T.I., Thomas, R. and Robinson, W.A. (1991) Role of recombinant Alpha-Interferon in the Treatment of Advanced Cutaneous Malignant Melanoma.Oncology 48, 365\u20138.","journal-title":"Oncology"},{"key":"BF01571406_CR32","first-page":"723","volume":"68","author":"S.E. Krown","year":"1984","unstructured":"Krown, S.E., Burk, M.W., Kirkwood, J.M.et al. (1984) Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase II trial.Cancer Treat. Rep. 68, 723\u20136.","journal-title":"Cancer Treat. Rep."},{"key":"BF01571406_CR33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/1097-0142(19830115)51:2<273::AID-CNCR2820510218>3.0.CO;2-K","volume":"51","author":"S. Retsas","year":"1983","unstructured":"Retsas, S., Priestman, T.J., Newton, K.A.et al. (1983) Evaluation of human lymphoblastoid interferon in advanced malignant melanoma.Cancer 51, 273\u20136.","journal-title":"Cancer"},{"key":"BF01571406_CR34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000226693","volume":"46","author":"M.R. Sertoli","year":"1989","unstructured":"Sertoli, M.R., Bernengo, M.G., Ardizzoni, A.et al. (1989) Phase II Trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.Oncology 46, 96\u20138.","journal-title":"Oncology"},{"issue":"6","key":"BF01571406_CR35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00000421-198812000-00013","volume":"11","author":"E.T. Creagan","year":"1988","unstructured":"Creagan, E.T., Schaid, D.J., Ahmann, D.L.et al. (1988) Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.Am. J. Clin. Oncol. (CCT).11 (6), 652\u20139.","journal-title":"Am. J. Clin. Oncol. (CCT)."},{"key":"BF01571406_CR36","first-page":"231","volume":"4","author":"R. Kerr","year":"1985","unstructured":"Kerr, R., Ayoob, M., Goldberg, R.et al. (1985) Treatment of metastatic malignant melanoma with human leukocyte interferon (IFN): Profile of 5 complete responders.Proc. Am. Soc. Clin. Oncol. 4, 231.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","volume":"4","author":"J.R. Quesada","year":"1986","unstructured":"Quesada, J.R., Talpaz, M., Rios, A.et al. (1986) Clinical toxicity of interferons in cancer patients: A review.J. Clin. Oncol. 4, 234\u201343.","journal-title":"J. Clin. Oncol."},{"key":"BF01571406_CR38","doi-asserted-by":"crossref","first-page":"180S","DOI":"10.1111\/1523-1747.ep12875497","volume":"95","author":"J.M. Kirkwood","year":"1990","unstructured":"Kirkwood, J.M. and Ernstoff, M.S. (1990) Role of interferon in the therapy of melanoma.J. Invest. Dermatol. 95, 180S-5S.","journal-title":"J. Invest. Dermatol."},{"issue":"549","key":"BF01571406_CR39","first-page":"52","volume":"552","author":"P. Grohn","year":"1989","unstructured":"Grohn, P. Nimustine, dacarbazine and recombinant interferon alfa 2a in metastatic malignant melanoma.Acta Chir. Scand. 552 (549), 52\u20135, (1989).","journal-title":"Acta Chir. Scand."},{"key":"BF01571406_CR40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0959-8049(05)80072-3","volume":"28","author":"P. Grohn","year":"1992","unstructured":"Grohn, P., Kumpulainen, E., Nuortio, L.et al. (1992) A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.Eur. J. Cancer 28, 441\u20133.","journal-title":"Eur. J. Cancer"},{"key":"BF01571406_CR41","first-page":"347","volume":"11","author":"N.H. Mulder","year":"1992","unstructured":"Mulder, N.H., de Vries, E.G.E., Sleijfer, D.T.et al. (1992) Dacarbazine (DTIC), Human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.Proc. Am. Soc. Clin. Oncol. 11, 347(#1195).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.1992.61","volume":"65","author":"N.H. Mulder","year":"1992","unstructured":"Mulder, N.H., de Vries, E.G.E., Sleijfer, D.T.et al. (1992) Dacarbazine (DTIC) human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.Br. J. Cancer 65, 303\u20134.","journal-title":"Br. J. Cancer"},{"key":"BF01571406_CR43","first-page":"346","volume":"11","author":"J. Richards","year":"1992","unstructured":"Richards, J., Mehta, N., Schroeder, L.et al. (1992) Sequential chemotherapy\/immunotherapy for metastatic melanoma.Proc. Am. Soc. Clin. Oncol. 11, 346(#1189).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR44","first-page":"343","volume":"11","author":"S. Legha","year":"1992","unstructured":"Legha, S., Plager, C., Ring, S.et al. (1992) A phase II study of biochemotherapy using interleukin 2 (IL2) + Interferon alpha-2a (IFN) in combination with cisplatin (C) vinblastin (V) and (DTIC)(D) in patients with metastatic melanoma.Proc. Am. Soc. Clin. Oncol. 11, 343(#1179).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR45","first-page":"343","volume":"11","author":"D. Thomson","year":"1992","unstructured":"Thomson, D., Adena, M., McLeod, G.R.C.et al. (1992) Interferon-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomized trial QMP8704.Proc. Am. Soc. Clin. Oncol. 11, 343(#1177).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR46","first-page":"345","volume":"11","author":"M.R. Sertoli","year":"1992","unstructured":"Sertoli, M.R., Queirolo, P., Bajetta, E.et al. (1992) Dacarbazine (DTIC) with or without recombinant interferon alpha-2a at different doses in the treatment of stage IV melanoma patients. Preliminary results of a randomized trial.Proc. Am. Soc. Clin. Oncol. 11, 345(#1185).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR47","first-page":"288","volume":"8","author":"R. Kerr","year":"1989","unstructured":"Kerr, R., Pippen, P., Mermel, R.et al. (1989) Treatment of metastatic malignant melanoma with a combination of interferon alpha-2a (IFN alpha-2a; Roferon) and dacarbazine (DTIC).Proc. Am. Soc. Clin. Oncol. 8, 288.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR48","first-page":"286","volume":"8","author":"E. Bajetta","year":"1989","unstructured":"Bajetta, E., Negretti, E., Giannotti, B.et al. (1989) Phase II study of interferon alpha-2a (rIFN alpha-2a) and dacarbazine (DTIC) in metastatic melanoma (MM).Proc. Am. Soc. Clin. Oncol. 8, 286.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BF01571406_CR49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-96-5-549","volume":"96","author":"J.U. Gutterman","year":"1982","unstructured":"Gutterman, J.U., Fein, S., Quesada, J.R.et al. (1982) Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.Ann. Intern. Med. 96, 549.","journal-title":"Ann. Intern. Med."},{"key":"BF01571406_CR50","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJM198305053081806","volume":"308","author":"S.E. Krown","year":"1983","unstructured":"Krown, S.E., Real, F.X., Cunningham-Rundles, S.et al. (1983) Preliminary observation on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi\u2019s sarcoma.N. Engl. J. Med. 308, 1071\u201376.","journal-title":"N. Engl. J. Med."},{"key":"BF01571406_CR51","first-page":"1041","volume":"70","author":"J.R. Quesada","year":"1983","unstructured":"Quesada, J.R. and Gutterman, J.U. (1983) Clinical study of recombinant DNA produced leukocyte interferon in an intermittent schedule in cancer patients.J. Natl. Cancer Inst. 70, 1041\u20136.","journal-title":"J. Natl. Cancer Inst."},{"key":"BF01571406_CR52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0002-9343(84)90097-4","volume":"77","author":"J.R. Quesada","year":"1984","unstructured":"Quesada, J.R., Hawkins, M., Merigan, T.C.et al. (1984) A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma.Am. J. Med. 77, 427\u201332.","journal-title":"Am. J. Med."},{"key":"BF01571406_CR53","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.1985.3.11.1522","volume":"3","author":"J.R. Quesada","year":"1985","unstructured":"Quesada, J.R., Rios, A., Swanson, D.et al. (1985) Antitumor activity of recombinant-derived interferon alpha (rIFN\u03b1A) in metastatic renal carcinoma.J. Clin. Oncol. 3, 1522\u201328.","journal-title":"J. Clin. Oncol."},{"key":"BF01571406_CR54","unstructured":"Shah, I., Band, J. and Rudnick, S. (1982) Pharmacokinetics and tolerance of intravenous recombinant alpha-2 interferon (alpha-2IFN) in patients with lymphoproliferative malignancies. (Abstr)Clin. Res. 30, 732A."},{"key":"BF01571406_CR55","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0277-5379(83)90053-6","volume":"19","author":"M.B. Edelstein","year":"1983","unstructured":"Edelstein, M.B., Schellekens, H., Laurent, T. and Ganci, L. (1983) A Phase I clinical tolerance study of rDNA alpha-2 human interferon in patients with non-reticulo-endothelial system malignancies.Eur. J. Cancer 19, 891\u20134.","journal-title":"Eur. J. Cancer"},{"key":"BF01571406_CR56","first-page":"40","volume":"71","author":"B. Bretandeau","year":"1984","unstructured":"Bretandeau, B., Palangie, T., Giralt, E.et al. (1984) Phase I trial of tolerance to increasing doses of recombinant DNA human alpha interferon in patients with advanced cancer.Cancer 71, 40\u20139.","journal-title":"Cancer"},{"key":"BF01571406_CR57","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.1984.2.9.1012","volume":"2","author":"H.B. Muss","year":"1984","unstructured":"Muss, H.B., Kempf, R.A., Martino, S.et al. (1984) A Phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.J. Clin. Oncol. 2, 1012\u201316.","journal-title":"J. Clin. Oncol."},{"key":"BF01571406_CR58","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/1097-0142(19860415)57:8+<1709::AID-CNCR2820571315>3.0.CO;2-F","volume":"57","author":"G.J. Jones","year":"1986","unstructured":"Jones, G.J. and Itri, L.M. (1986) Safety and tolerance of recombinant alfa-2b in cancer patients.Cancer (Suppl) 57, 1709\u201315.","journal-title":"Cancer (Suppl)"},{"key":"BF01571406_CR59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(86)90013-6","volume":"80","author":"R.J. Spiegel","year":"1986","unstructured":"Spiegel, R.J., Spicehandler, J.R., Jacobs, S.L.et al. (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon.Am. J. Med. 80, 223\u20137.","journal-title":"Am. J. Med."},{"key":"BF01571406_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.1986.6.1","volume":"6","author":"A. Coates","year":"1986","unstructured":"Coates, A., Rallings, M., Hersey, P. and Swanson, C. (1986) Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma.J. Interferon Res. 6, 1\u20134.","journal-title":"J. Interferon Res."},{"issue":"6","key":"BF01571406_CR61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/bjc.1985.127","volume":"51","author":"P. Hersey","year":"1985","unstructured":"Hersey, P., Hasic, E., MacDonald, M.et al. (1985) Effects of recombinant leukocyte interferon (rIFN alpha A) on tumor growth and immune responses in patients with metastatic melanoma.Br. J. Cancer 51(6), 815\u201326.","journal-title":"Br. J. Cancer"},{"issue":"8","key":"BF01571406_CR62","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1987.5.8.1240","volume":"5","author":"S.S. Legha","year":"1987","unstructured":"Legha, S.S., Papadopoulos, N.E., Plager, C.et al. (1987) Clinical evaluation of recombinant alfa-2a (Roferon-a) in metastatic melanoma using two different schedules.J. Clin. Oncol. 5(8), 1240\u20136, 5(11):1858E.","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"BF01571406_CR63","first-page":"401","volume":"105","author":"U. Elsasser-Beile","year":"1987","unstructured":"Elsasser-Beile, U. and Drews, H.(1987) Interferons in the treatment of malignant melanoma. Results of clinical studies.Fortschr. Med. 105(21), 401\u2013403,442.","journal-title":"Fortschr. Med."},{"issue":"5","key":"BF01571406_CR64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00390040","volume":"113","author":"A. Steiner","year":"1987","unstructured":"Steiner, A., Wolf, C. and Pehamberger, H. (1987) Comparison of the effects of three different regimens of recombinant interferons (rIFN alpha, rIFN gamma, rIFN alpha + cimetidine) in disseminated malignant melanoma.J. Cancer Res. Clin. Oncol. 113(5), 459\u2013465.","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BF01571406_CR65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0171-2985(86)80109-7","volume":"172","author":"W.A. Robinson","year":"1986","unstructured":"Robinson, W.A., Mughal, T.I., Thomas, M.R.et al. (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha-2.Immunobiology 172, 275\u201382.","journal-title":"Immunobiology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01571406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01571406\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01571406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T02:02:53Z","timestamp":1683079373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01571406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["BF01571406"],"URL":"https:\/\/doi.org\/10.1007\/bf01571406","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}